Discussion about this post

User's avatar
Overcoming Bias Commenter's avatar

SRT501 , a GSK resveratrol based drug that will likely never get marketed because it may be too close to regular resveratrol, is being tested on 15 colon/liver cancer patients. 5g a day.

The resuts are due this month.

One promising sign is last month's study that showed regular resvertarol stopped the spread of cancer (liver?) in 70% of mice taking it as opposed to jusr 4% in the control group.

Multiple Myeloma results for SRT501 will be in late next year. Alzheimes and Prakisons also on dock for trials.

It looks like GSK is banking on the much more powerful SRT1701 or SRT2401 drugs they hope to market in 2012-2014.

Expand full comment
Overcoming Bias Commenter's avatar

It's weird, but it actually has some truth behind it. An analysis of health care costs (discussed in Overtreated) finds that the more religious, "red" areas in the middle of the country have a much higher expenditure on this type of questionably useful end-of-life prolonging care as compared to the coastal "blue" areas, which are significantly less religious.

Of course, saying that it is specifically religion that causes this difference doesn't follow. But it would not surprise me if the same type of mentality supports both high religiosity and high faith in ineffectual medical intervention.

Expand full comment
37 more comments...

No posts